CRISPR Therapeutics continues to make major commercial and clinical strides, highlighted by surging global sales for its FDA-approved sickle cell and beta-thalassemia therapy, Casgevy, which recently surpassed quarterly revenue milestones with strong year-over-year growth. Additionally, the company is advancing its next-generation in vivo gene-editing clinical pipeline—such as CTX310 for cardiovascular and lipid disorders—showing promising early-phase trial results and expanding its therapeutic scope.